AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4D Molecular Therapeutics... (FDMT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.60

-0.12 (-2.54%)

At close: Jan 28, 2025, 1:44 PM

4D Molecular Therapeutics Inc. Revenue Breakdown

Quarter	Sep 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021
Collaboration And License Revenue Revenue	3.00K	28.00K	0	20.01M	239.00K	298.00K	1.25M	500.00K	162.00K	1.22M	12.00K	64.00K	14.58M	2.00M
Collaboration And License Revenue Revenue Growth	-89.29%	n/a	-100.00%	+8271.55%	-19.80%	-76.10%	+149.40%	+208.64%	-86.71%	+10058.33%	-81.25%	-99.56%	+629.00%	n/a

Revenue by Geography

Quarter	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Netherlands Revenue	567.00K	3.09M	736.00K	742.00K
Netherlands Revenue Growth	-81.67%	+320.38%	-0.81%	n/a
United States Revenue	20.16M	35.00K	121.00K	-27.00K
United States Revenue Growth	+57488.57%	-71.07%	-548.15%	n/a

Operating Expense Breakdown

Quarter	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018
Selling, General, and Administrative Revenue	12.65M	10.60M	8.70M	10.61M	9.11M	8.79M	7.99M	8.47M	8.05M	8.17M	8.23M	7.33M	8.19M	6.95M	5.54M	6.84M	3.68M	3.06M	3.65M	5.96M	3.05M	2.44M	2.44M	1.98M	1.98M	1.10M	1.10M
Selling, General, and Administrative Revenue Growth	+19.34%	+21.85%	-17.96%	+16.38%	+3.65%	+10.00%	-5.61%	+5.11%	-1.36%	-0.78%	+12.31%	-10.49%	+17.75%	+25.44%	-18.96%	+85.77%	+20.25%	-16.20%	-38.68%	+95.25%	+24.98%	n/a	+23.05%	n/a	+80.57%	n/a	n/a
Research and Development Revenue	38.48M	31.86M	27.87M	26.03M	25.07M	23.58M	22.41M	21.50M	18.94M	20.42M	19.38M	17.53M	15.84M	15.22M	12.77M	12.61M	11.55M	15.72M	13.16M	12.36M	9.37M	8.49M	8.49M	5.08M	5.08M	4.10M	4.10M
Research and Development Revenue Growth	+20.79%	+14.32%	+7.08%	+3.84%	+6.28%	+5.23%	+4.24%	+13.52%	-7.26%	+5.37%	+10.57%	+10.66%	+4.05%	+19.22%	+1.30%	+9.09%	-26.49%	+19.47%	+6.46%	+31.84%	+10.38%	n/a	+67.27%	n/a	+23.71%	n/a	n/a